Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) will be reporting earnings this Wednesday after market close.

Analysts anticipate Exact Sciences to report an earnings per share (EPS) of $0.02. Anticipation surrounds Exact Sciences's ...

The Cologuard Plus test is being offered as an in-network service to eligible Humana Medicare Advantage members.

Baron Funds, an investment management company, released its “Baron Health Care Fund” second-quarter 2025 investor letter. A ...

Notably, Exact Sciences is also working on its own blood-based test for colorectal cancer screening. It's important to note, experts expect blood tests to be less accurate than stool-based screeners.

Exact Sciences Earnings: Robust Growth Due to Screening, New Products Launching on Schedule Jay Lee May 5, 2025 ...

Exact Sciences is beginning to stem losses and is continuing to grow revenue at a reasonable clip. Despite this, GAAP profitability is still far into the future, and the 2023 guidance is mediocre.

Last year, Exact Sciences burned through $223.6 million in cash just from its day-to-day operations. And that was a significant increase from the $102.2 million it used up in the previous year.

First, more providers than ever are now prescribing Cologuard. Exact Sciences recently reported that around 147,000 providers have adopted the DNA cancer test, which reflects a CAGR of 76% since 2014.

Exact Sciences is a $6.2 billion company today, but if it doesn't get close to making ends meet by the end of the year, investors buying the stock on the recent dip could still suffer heavy losses.

Exact Sciences Corporation bulls have some big numbers on their side. If 40% of the eligible U.S. population used its home screening kit every few years, the company could haul in around $5.4 ...